Patient characteristics
| Characteristic . | . | Donor and HCT group . | . | ||
|---|---|---|---|---|---|
| Haploidentical . | Matched sibling . | 8/8 HLA-MUD . | 7/8 HLA-MUD . | UCB . | |
| No. of patients | 393 | 1627 | 1646 | 230 | 305 |
| No. of centers | 92 | 206 | 181 | 90 | 79 |
| Median follow-up, mo (range) | 24 (3-67) | 26 (3-72) | 35 (3-74) | 35 (3-64) | 35 (3-64) |
| Median recipient age, y (range) | 41 (18-74) | 42 (18-75) | 43 (18-77) | 38 (18-70) | 37 (18-70) |
| Karnofsky performance status (%) | |||||
| ≥90 | 233 (59) | 1046 (64) | 995 (60) | 163 (71) | 196 (64) |
| <90 | 152 (39) | 542 (33) | 629 (38) | 65 (28) | 107 (35) |
| Missing | 8 (2) | 39 (2) | 22 (1) | 2 (<1) | 2 (<1) |
| No. of male recipients | 214 (54) | 969 (60) | 976 (59) | 134 (58) | 176 (58) |
| HCT-CI score | |||||
| 0 | 81 (21) | 592 (36) | 405 (25) | 53 (23) | 89 (29) |
| 1 | 57 (15) | 221 (14) | 224 (14) | 35 (15) | 42 (14) |
| 2 | 61 (16) | 228 (14) | 266 (16) | 37 (16) | 46 (15) |
| 3+ | 194 (49) | 552 (34) | 745 (45) | 104 (45) | 125 (41) |
| Missing | 0 | 34 (2) | 6 (<1) | 1 (<1) | 3 (<1) |
| Race/ethnicity* | |||||
| Hispanic White | 87 (22) | 246 (15) | 136 (8) | 42 (18) | 64 (21) |
| Non-Hispanic White | 170 (43) | 846 (52) | 1226 (74) | 113 (49) | 150 (49) |
| Black | 59 (15) | 74 (5) | 53 (3) | 19 (8) | 27 (9) |
| Asian | 22 (6) | 111 (7) | 64 (4) | 10 (4) | 22 (7) |
| Other/not specified | 55 (14) | 350 (22) | 167 (10) | 46 (20) | 42 (14) |
| Immunophenotype | |||||
| T cell | 25 (6) | 201 (12) | 186 (11) | 27 (12) | 36 (12) |
| B cell | 330 (84) | 1316 (81) | 1319 (80) | 185 (80) | 246 (81) |
| Not specified | 38 (10) | 110 (7) | 141 (9) | 18 (8) | 23 (8) |
| Cytogenetic risk score† | |||||
| Normal | 91 (23) | 320 (20) | 335 (20) | 52 (23) | 63 (21) |
| Poor | 222 (56) | 750 (46) | 855 (52) | 101 (44) | 154 (50) |
| Missing/not tested/other | 80 (21) | 557 (34) | 456 (28) | 77 (33) | 88 (29) |
| Ph/BCR-ABL1-positive | 152 (46) | 562 (43) | 614 (47) | 80 (43) | 122 (50) |
| Remission status | |||||
| CR1, MRD positive | 112 (28) | 513 (32) | 509 (31) | 58 (25) | 78 (26) |
| CR1, MRD negative | 143 (36) | 644 (40) | 697 (42) | 85 (37) | 124 (41) |
| CR1, MRD missing | 14 (4) | 145 (9) | 59 (4) | 6 (3) | 10 (3) |
| CR2 | 105 (27) | 296 (18) | 334 (20) | 62 (27) | 74 (24) |
| ≥CR3 | 19 (5) | 29 (2) | 47 (3) | 19 (8) | 19 (6) |
| Time from diagnosis to HCT (CR1 only) (mo) | |||||
| 0-5 | 130 (48) | 842 (65) | 744 (59) | 56 (38) | 93 (44) |
| 6-11 | 115 (43) | 388 (30) | 463 (37) | 81 (54) | 102 (48) |
| ≥12 | 24 (9) | 72 (6) | 58 (5) | 12 (8) | 17 (8) |
| Conditioning regimen | |||||
| MAC, TBI-based | 163 (41) | 984 (60) | 950 (58) | 139 (60) | 217 (71) |
| MAC, chemotherapy-based | 63 (16) | 323 (20) | 312 (19) | 51 (22) | 11 (4) |
| RIC/NMA | 167 (42) | 316 (19) | 383 (23) | 39 (17) | 76 (25) |
| Missing | 0 | 4 (<1) | 1 (<1) | 1 (<1) | 1 (<1) |
| Donor/recipient sex | |||||
| Female donor/male recipient | 82 (21) | 415 (26) | 244 (15) | 42 (18) | 161 (53) |
| other donor/recipient | 311 (79) | 1212 (74) | 1396 (85) | 188 (82) | 137 (45) |
| Missing | 0 | 0 | 6 (<1) | 0 | 7 (2) |
| Donor/recipient CMV serostatus | |||||
| +/+ | 206 (52) | 859 (53) | 506 (31) | 90 (39) | 0 |
| +/− | 31 (8) | 144 (9) | 197 (12) | 25 (11) | 0 |
| −/+ | 83 (21) | 287 (18) | 553 (34) | 64 (28) | 0 |
| −/− | 72 (18) | 306 (19) | 382 (23) | 50 (22) | 0 |
| UCB–/recipient+ | 0 | 0 | 0 | 0 | 200 (66) |
| UCB–/recipient– | 0 | 0 | 0 | 0 | 100 (33) |
| Missing | 1 (<1) | 31 (2) | 8 (<1) | 1 (<1) | 5 (2) |
| Median donor age, y (range) | 35 (10-74) | 41 (9-75) | 28 (18-60) | 31 (19-60) | NA |
| Graft source | |||||
| Bone marrow | 160 (41) | 230 (14) | 316 (19) | 67 (29) | — |
| Peripheral blood | 233 (59) | 1397 (86) | 1330 (81) | 163 (71) | — |
| GVHD prophylaxis | |||||
| CNI + MTX ± others | 0 | 1107 (68) | 1165 (71) | 162 (70) | 7 (2) |
| CNI + MMF ± others | 0 | 236 (15) | 191 (12) | 18 (8) | 265 (87) |
| CNI + others | 0 | 118 (7) | 141 (9) | 13 (6) | 6 (2) |
| CNI alone | 0 | 66 (4) | 58 (4) | 5 (2) | 14 (5) |
| PTCy + CNI ± MMF | 393 (100) | 75 (5) | 73 (4) | 29 (13) | 2 (<1) |
| Other prophylaxis | 0 | 17 (1) | 13 (<1) | 2 (<1) | 10 (3) |
| Missing | 0 | 8 (<1) | 5 (<1) | 1 (<1) | 1 (<1) |
| In vivo T-cell depletion | |||||
| Antithymocyte globulin | 5 (1) | 76 (5) | 561 (34) | 116 (50) | 39 (13) |
| Alemtuzumab | 0 | 33 (2) | 62 (4) | 6 (3) | 0 |
| None | 388 (99) | 1505 (93) | 1010 (61) | 105 (46) | 265 (87) |
| Missing | 0 | 13 (<1) | 13 (<1) | 3 (1) | 1 (<1) |
| Characteristic . | . | Donor and HCT group . | . | ||
|---|---|---|---|---|---|
| Haploidentical . | Matched sibling . | 8/8 HLA-MUD . | 7/8 HLA-MUD . | UCB . | |
| No. of patients | 393 | 1627 | 1646 | 230 | 305 |
| No. of centers | 92 | 206 | 181 | 90 | 79 |
| Median follow-up, mo (range) | 24 (3-67) | 26 (3-72) | 35 (3-74) | 35 (3-64) | 35 (3-64) |
| Median recipient age, y (range) | 41 (18-74) | 42 (18-75) | 43 (18-77) | 38 (18-70) | 37 (18-70) |
| Karnofsky performance status (%) | |||||
| ≥90 | 233 (59) | 1046 (64) | 995 (60) | 163 (71) | 196 (64) |
| <90 | 152 (39) | 542 (33) | 629 (38) | 65 (28) | 107 (35) |
| Missing | 8 (2) | 39 (2) | 22 (1) | 2 (<1) | 2 (<1) |
| No. of male recipients | 214 (54) | 969 (60) | 976 (59) | 134 (58) | 176 (58) |
| HCT-CI score | |||||
| 0 | 81 (21) | 592 (36) | 405 (25) | 53 (23) | 89 (29) |
| 1 | 57 (15) | 221 (14) | 224 (14) | 35 (15) | 42 (14) |
| 2 | 61 (16) | 228 (14) | 266 (16) | 37 (16) | 46 (15) |
| 3+ | 194 (49) | 552 (34) | 745 (45) | 104 (45) | 125 (41) |
| Missing | 0 | 34 (2) | 6 (<1) | 1 (<1) | 3 (<1) |
| Race/ethnicity* | |||||
| Hispanic White | 87 (22) | 246 (15) | 136 (8) | 42 (18) | 64 (21) |
| Non-Hispanic White | 170 (43) | 846 (52) | 1226 (74) | 113 (49) | 150 (49) |
| Black | 59 (15) | 74 (5) | 53 (3) | 19 (8) | 27 (9) |
| Asian | 22 (6) | 111 (7) | 64 (4) | 10 (4) | 22 (7) |
| Other/not specified | 55 (14) | 350 (22) | 167 (10) | 46 (20) | 42 (14) |
| Immunophenotype | |||||
| T cell | 25 (6) | 201 (12) | 186 (11) | 27 (12) | 36 (12) |
| B cell | 330 (84) | 1316 (81) | 1319 (80) | 185 (80) | 246 (81) |
| Not specified | 38 (10) | 110 (7) | 141 (9) | 18 (8) | 23 (8) |
| Cytogenetic risk score† | |||||
| Normal | 91 (23) | 320 (20) | 335 (20) | 52 (23) | 63 (21) |
| Poor | 222 (56) | 750 (46) | 855 (52) | 101 (44) | 154 (50) |
| Missing/not tested/other | 80 (21) | 557 (34) | 456 (28) | 77 (33) | 88 (29) |
| Ph/BCR-ABL1-positive | 152 (46) | 562 (43) | 614 (47) | 80 (43) | 122 (50) |
| Remission status | |||||
| CR1, MRD positive | 112 (28) | 513 (32) | 509 (31) | 58 (25) | 78 (26) |
| CR1, MRD negative | 143 (36) | 644 (40) | 697 (42) | 85 (37) | 124 (41) |
| CR1, MRD missing | 14 (4) | 145 (9) | 59 (4) | 6 (3) | 10 (3) |
| CR2 | 105 (27) | 296 (18) | 334 (20) | 62 (27) | 74 (24) |
| ≥CR3 | 19 (5) | 29 (2) | 47 (3) | 19 (8) | 19 (6) |
| Time from diagnosis to HCT (CR1 only) (mo) | |||||
| 0-5 | 130 (48) | 842 (65) | 744 (59) | 56 (38) | 93 (44) |
| 6-11 | 115 (43) | 388 (30) | 463 (37) | 81 (54) | 102 (48) |
| ≥12 | 24 (9) | 72 (6) | 58 (5) | 12 (8) | 17 (8) |
| Conditioning regimen | |||||
| MAC, TBI-based | 163 (41) | 984 (60) | 950 (58) | 139 (60) | 217 (71) |
| MAC, chemotherapy-based | 63 (16) | 323 (20) | 312 (19) | 51 (22) | 11 (4) |
| RIC/NMA | 167 (42) | 316 (19) | 383 (23) | 39 (17) | 76 (25) |
| Missing | 0 | 4 (<1) | 1 (<1) | 1 (<1) | 1 (<1) |
| Donor/recipient sex | |||||
| Female donor/male recipient | 82 (21) | 415 (26) | 244 (15) | 42 (18) | 161 (53) |
| other donor/recipient | 311 (79) | 1212 (74) | 1396 (85) | 188 (82) | 137 (45) |
| Missing | 0 | 0 | 6 (<1) | 0 | 7 (2) |
| Donor/recipient CMV serostatus | |||||
| +/+ | 206 (52) | 859 (53) | 506 (31) | 90 (39) | 0 |
| +/− | 31 (8) | 144 (9) | 197 (12) | 25 (11) | 0 |
| −/+ | 83 (21) | 287 (18) | 553 (34) | 64 (28) | 0 |
| −/− | 72 (18) | 306 (19) | 382 (23) | 50 (22) | 0 |
| UCB–/recipient+ | 0 | 0 | 0 | 0 | 200 (66) |
| UCB–/recipient– | 0 | 0 | 0 | 0 | 100 (33) |
| Missing | 1 (<1) | 31 (2) | 8 (<1) | 1 (<1) | 5 (2) |
| Median donor age, y (range) | 35 (10-74) | 41 (9-75) | 28 (18-60) | 31 (19-60) | NA |
| Graft source | |||||
| Bone marrow | 160 (41) | 230 (14) | 316 (19) | 67 (29) | — |
| Peripheral blood | 233 (59) | 1397 (86) | 1330 (81) | 163 (71) | — |
| GVHD prophylaxis | |||||
| CNI + MTX ± others | 0 | 1107 (68) | 1165 (71) | 162 (70) | 7 (2) |
| CNI + MMF ± others | 0 | 236 (15) | 191 (12) | 18 (8) | 265 (87) |
| CNI + others | 0 | 118 (7) | 141 (9) | 13 (6) | 6 (2) |
| CNI alone | 0 | 66 (4) | 58 (4) | 5 (2) | 14 (5) |
| PTCy + CNI ± MMF | 393 (100) | 75 (5) | 73 (4) | 29 (13) | 2 (<1) |
| Other prophylaxis | 0 | 17 (1) | 13 (<1) | 2 (<1) | 10 (3) |
| Missing | 0 | 8 (<1) | 5 (<1) | 1 (<1) | 1 (<1) |
| In vivo T-cell depletion | |||||
| Antithymocyte globulin | 5 (1) | 76 (5) | 561 (34) | 116 (50) | 39 (13) |
| Alemtuzumab | 0 | 33 (2) | 62 (4) | 6 (3) | 0 |
| None | 388 (99) | 1505 (93) | 1010 (61) | 105 (46) | 265 (87) |
| Missing | 0 | 13 (<1) | 13 (<1) | 3 (1) | 1 (<1) |
BCR-ABL, breakpoint cluster region-Abelson murine leukemia; CMV, cytomegalovirus; CNI, calcineurin inhibitor; MAC, myeloablative conditioning; MMF, mycophenolate mofetil; MTX, methotrexate; NA, not applicable; NMA, non-myeloablative.
Other/not specified: Native American (n = 30), Pacific Islander (n = 20), non-resident of the United States (n = 291), not specified (n = 156), Hispanic, excluding White Hispanic (n = 213).
CIBMTR cytogenetics criteria definition: Poor: Ph+/t(9:22)/BCR-ABL1, t(4:11), 11q23/MLL/KMT2A, hypodiploid (<45), t(8:14), complex (≥3 abnormalities), iAMP21; normal: without any abnormality; other: abnormality count of 1 or 2 abnormalities.